News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
697,923 Results
Type
Article (40116)
Company Profile (337)
Press Release (657470)
Section
Business (206819)
Career Advice (2062)
Deals (35830)
Drug Delivery (94)
Drug Development (82196)
Employer Resources (172)
FDA (16175)
Job Trends (15125)
News (349570)
Policy (32776)
Tag
Academia (2550)
Alliances (49992)
Alzheimer's disease (1291)
Approvals (16139)
Artificial intelligence (149)
Bankruptcy (357)
Best Places to Work (11703)
Biotechnology (239)
Breast cancer (193)
Cancer (1411)
Cardiovascular disease (114)
Career advice (1716)
Cell therapy (291)
Clinical research (65787)
Collaboration (502)
Compensation (290)
COVID-19 (2565)
C-suite (114)
Data (1416)
Diabetes (178)
Diagnostics (6195)
Earnings (85934)
Employer resources (150)
Events (112529)
Executive appointments (416)
FDA (16884)
Funding (447)
Gene therapy (204)
GLP-1 (627)
Government (4373)
Healthcare (18791)
Infectious disease (2658)
Inflammatory bowel disease (113)
Interviews (326)
IPO (16592)
Job creations (3832)
Job search strategy (1465)
Layoffs (434)
Legal (7913)
Lung cancer (204)
Manufacturing (214)
Medical device (13233)
Medtech (13238)
Mergers & acquisitions (19435)
Metabolic disorders (473)
Neuroscience (1625)
NextGen: Class of 2025 (6559)
Non-profit (4486)
Northern California (1748)
Obesity (267)
Opinion (201)
Parkinson's disease (100)
Patents (123)
People (57340)
Phase I (20500)
Phase II (29031)
Phase III (21527)
Pipeline (522)
Postmarket research (2570)
Preclinical (8694)
Radiopharmaceuticals (247)
Rare diseases (269)
Real estate (6015)
Regulatory (21962)
Research institute (2333)
Resumes & cover letters (354)
Southern California (1517)
Startups (3644)
United States (15733)
Vaccines (577)
Weight loss (191)
Date
Today (166)
Last 7 days (311)
Last 30 days (1818)
Last 365 days (35175)
2025 (295)
2024 (35770)
2023 (40662)
2022 (51785)
2021 (56339)
2020 (54539)
2019 (46983)
2018 (35386)
2017 (32635)
2016 (32060)
2015 (38110)
2014 (32006)
2013 (26894)
2012 (29013)
2011 (29669)
2010 (27706)
Location
Africa (736)
Arizona (199)
Asia (38600)
Australia (6232)
California (3960)
Canada (1489)
China (339)
Colorado (176)
Connecticut (185)
Europe (83117)
Florida (560)
Georgia (137)
Illinois (396)
Indiana (230)
Maryland (659)
Massachusetts (3072)
Michigan (177)
Minnesota (299)
New Jersey (1141)
New York (1121)
North Carolina (796)
Northern California (1748)
Ohio (149)
Pennsylvania (952)
South America (1118)
Southern California (1517)
Texas (574)
Utah (112)
Washington State (412)
697,923 Results for "theravance biopharma inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
Theravance Biopharma, Inc. (“Theravance Biopharma” or the “Company”) (NASDAQ: TBPH) today announced financial and operational results for the first quarter of 2024.
May 13, 2024
·
17 min read
Business
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Theravance Biopharma, Inc. (“Theravance Biopharma” or the “Company”) (NASDAQ: TBPH) today announced financial and operational results for the fourth quarter of 2023 and full-year ended December 31, 2023.
February 26, 2024
·
23 min read
Theravance Biopharma to Participate in an Upcoming May 2024 Investor Conference
Theravance Biopharma, Inc. will participate in a Fireside Chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ Monday, May 20 at 11:30 AM EDT and will be hosting in-person meetings with the investment community at the conference.
May 9, 2024
·
1 min read
Business
Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024
Theravance Biopharma, Inc. will report its first quarter 2024 financial results and provide a business update after market close on Monday, May 13, 2024.
April 29, 2024
·
1 min read
Business
Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors
Theravance Biopharma, Inc. (“Theravance” or the “Company”) (NASDAQ: TBPH) today announced the appointment to its Board of Directors of Jeremy Grant, who serves as a Special Advisor to Irenic Capital Management LP (“Irenic”).
December 21, 2023
·
8 min read
Business
Theravance Biopharma, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update
Theravance Biopharma, Inc. (“Theravance Biopharma” or the “Company”) (NASDAQ: TBPH) today announced financial and operational results for the third quarter of 2023.
November 7, 2023
·
23 min read
Theravance Biopharma to Participate in an Upcoming March 2024 Investor Conference
Theravance Biopharma, Inc. will participate in the CNS Corporate Panel Discussion at the TD Cowen 44th Annual Health Care Conference in Boston, MA on Tuesday, March 5 at 10:30 am ET.
February 22, 2024
·
1 min read
NextGen
BioSpace
’s NextGen Class of 2025 Leans Into Biopharma’s Hottest Trends
From ADCs and radiopharmaceuticals to cell and gene therapies, eager young startups are betting on advances in biopharma’s most competitive therapeutic spaces—and attracting dollars from Big Pharma.
January 7, 2025
·
4 min read
·
Heather McKenzie
Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine’s Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy on May 23, 2024
Theravance Biopharma, Inc. announced it will host a virtual KOL event on Thursday, May 23, 2024 from 10:00 AM to 11:30 AM ET, featuring Horacio Kaufmann, MD, FAAN and Italo Biaggioni, MD, who will discuss the unmet need and current treatment landscape for MSA patients with symptomatic nOH.
April 10, 2024
·
6 min read
Business
Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024
Theravance Biopharma, Inc. will report its fourth quarter and full year 2023 financial results and provide a business update after market close on Monday, February 26, 2024.
February 14, 2024
·
1 min read
1 of 69,793
Next
